Newborn Screening Market Trends Analysis Report 2025-2033: Focus on Instruments and Reagents & Assay Kits, Tandem Mass Spectrometry, Pulse Oximetry, Enzyme-Based Assays, DNA Assays, Electrophoresis

Dublin, Jan. 21, 2026 (GLOBE NEWSWIRE) -- The "Newborn Screening Market Size, Share & Trends Analysis Report by Product (Instruments and Reagents & Assay Kits), Technology (Tandem Mass Spectrometry, Pulse Oximetry, Enzyme-Based Assays, DNA Assays, Electrophoresis), Test Type and Region with Growth Forecasts, 2025-2033" has been added to ResearchAndMarkets.com's offering.

The global newborn screening market is poised for substantial growth, with projections indicating a rise from USD 900.63 million in 2024 to USD 1.79 billion by 2033, reflecting a CAGR of 8.1% from 2025 to 2033. Key factors driving this growth include an increasing neonatal population, rising congenital disease prevalence in newborns, heightened consumer awareness, and supportive governmental initiatives.

According to the United Nations Department of Economic and Social Affairs, the world anticipates approximately 132.4 million births in 2024. The World Health Organization reports that congenital disorders impact about 6% of all births globally. An in-depth study on congenital disabilities highlighted a significant number of children living with these conditions, a trend linked to technological advancements in screening methodologies. For example, Revvity, Inc. launched the EONIS Q system in November 2023, which enhances laboratory capabilities for spinal muscular atrophy (SMA) and severe combined immunodeficiency (SCID) testing in newborns.

Notably, congenital disorders are implicated in 240,000 newborn deaths annually within the first 28 days and significantly contribute to child mortality rates among those aged one month to five years. A study from Indian Pediatrics identifies congenital hypothyroidism and metabolic abnormalities with considerable prevalence in India, underscoring the growing need for efficient screening protocols, potentially accelerating market progress by 2030.

Globally, governmental programs and initiatives are setting a conducive stage for newborn screening market enhancement. Programs like the Next Generation Sequencing (NGS) pilot, which involved 100,000 babies in 2023, highlight genomic innovations in early screening. Collaborations, such as Illumina's involvement in international genomic investigations, emphasize the global commitment to advancing neonatal health through innovative screening methods.

The demand for newborn screening procedures is anticipated to be further amplified by advancements in technology, enabling the identification of up to 29 potential disorders, including galactosemia, phenylketonuria, and congenital hypothyroidism. Moreover, the CDC's introduction of advanced genetic disease diagnostics exemplifies strides in improving screening accuracy and reliability.

Why should you buy this report?

Key Attributes:

Newborn Screening Market Variables, Trends, & Scope

Companies Featured

Global Newborn Screening Market Report Segmentation 2021-2033

For more information about this report visit https://www.researchandmarkets.com/r/fn4avj

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment